CSD1603: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From 100s Menthol Cigarette Products

Not Applicable

Completed

• Conditions: Smoking
• Interventions: Other: PD21871AA; Other: PD21872AA

• Registration Number: NCT03063047
• Lead Sponsor: RAI Services Company

Brief Summary

This study will evaluate exposure to "tar" and nicotine from two menthol cigarette products and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette products. Mouth-level exposure is the measurement of substance trapped in the cigarette butt after smoking the cigarette.

Other purposes of this study are to:

* Compare the plasma cotinine, a byproduct of your body's processing of nicotine, levels found in users after smoking each of two different cigarettes.

* Find out the daily mouth-level exposure to cigarette "tar" and nicotine from smoking each of two different cigarettes in adult smokers.

* Determine if certain measures of nicotine dependence change based on the type of cigarette smoked

* To compare product liking and intent to use it again.

Detailed Description

The study will consist of one group of approximately 32 adult subjects randomly assigned to the order in which they will smoke two study menthol cigarette products (including one comparator product and one test product). Subjects will smoke each study product exclusively for approximately one week prior to a test visit, with a different product smoked each week over a two-week period. Cigarette butts will be collected the day prior to each test visit for determination of MLE "tar" and nicotine levels. Blood samples will be collected at each test visit for determination of plasma cotinine levels. Subjects will provide responses to questions during each test visit to assess their cigarette smoking and cigarette butt collection behavior during the preceding day.

Study Timeline

• Study Start: 2017-02-06
• Study First Submitted: 2017-02-20
• Study First Submitted QC: 2017-02-20
• Study First Posted: 2017-02-24
• Status Verified: 2017-03
• Primary Completion: 2017-03-13
• Study Completion: 2017-03-13
• Last Update Submitted: 2017-03-13
• Last Update Posted: 2017-03-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Able to read, understand, and willing to sign an Informed Consent Form (ICF).
• Generally healthy males and females, 21 years of age or older, at Screening-Enrollment Visit.
• Self-reports smoking at least seven cigarettes per day and inhaling the smoke.
• Usual brand of cigarette is one of the brand styles specified.
• Smoked usual brand for ≥ 3 months.
• Agrees to exclusively smoke the study cigarettes and not smoke or use any other tobacco or nicotine-containing products during the course of the study.
• Able to read and comprehend English.
• Able to safely perform the required study procedures, as determined by the Investigator.

Exclusion Criteria

• Self-reported history of heart disease, kidney disease, asthma or any other lung disease, diabetes, liver disease, hypertension, or hypercholesterolemia.
• At risk for heart disease, i.e., obesity (body mass index [BMI] ≥ 40 kg/m2), as determined by the Investigator.
• Females ≥ 35 years of age currently using systemic, estrogen-containing contraception, or hormone replacement therapy.
• Postponing a decision to quit smoking (defined as planning a quit attempt within 30 days of the Screening-Enrollment Visit) to participate in this study.
• Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days prior to the Screening-Enrollment Visit.
• Females who test positive for pregnancy, are pregnant or breastfeeding, or plan to become pregnant during the course of the study.
• Determined by the Investigator to be inappropriate for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
PD21871AA, PD21872AA	PD21871AA	Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
PD21871AA, PD21872AA	PD21872AA	Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
PD21872AA, PD21871AA	PD21871AA	Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
PD21872AA, PD21871AA	PD21872AA	Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.

Primary Outcome Measures

Name	Time	Method
Mouth-level exposure (MLE) "tar" per cigarette and MLE nicotine per cigarette.	2 weeks	To compare the per cigarette MLE parameters (MLE "tar" per cigarette and MLE nicotine per cigarette) from smoking PD21871AA with those from smoking PD21872AA in adult smokers.

Trial Locations

Locations (1)

DaVita Clinical Research; 🇺🇸 Lakewood, Colorado, United States